Dec 19, 2024 · The HER2–ultra-low is when we see some expression of the HER2 protein in 1%-10% of invasive breast cancer cells. That used to be called HER2 0, and now we are calling it ultra-low.

Using either HER2/CEP17 ratio >2.2 or ≥2.0 as criterion for HER2 amplification, high levels of concordance were observed between automated and manual FISH (concordance rate 96%, κ coefficient 0 ...

In single-probe assays gene amplification is defined as a mean number of HER2 copy number ≥6.0 signals per cell, while in the dual-probe assay the FISH is positive when HER2/CEP17 ratio is ≥2. ...

Feb 28, 2025 · The same is true for patients with ER-positive disease. If your disease was ER positive and HER2 positive, you were excluded from all of our recent trials focusing on ER-positive disease.

English Edition. Medscape. English; Deutsch; Español; Français; Português; Univadis

In 4 cases, HER2 amplification status (HER2/CEP17 ratio >2.2) was discordant between manual and automated FISH.HER2/CEP17 ratios of these cases were 2.62, 2.74, 2.5, and 3.14 for manual FISH, and ...

Results: Twenty patients (6.4%) had HER2-positive disease by immunohistochemistry and FISH. Only 7 (32%) patients (median age, 56 years; range, 48-68 years) met eligibility criteria; they had ...

November 4, 2009 (Chicago, Illinois) — Universal testing of breast cancer tissue for Her-2/neu status with fluorescence in situ hybridization (FISH), as some have proposed, does not increase the ...

English Edition. Medscape. English; Deutsch; Español; Français; Português; Univadis

Will your patient benefit from trastuzumab? New research using quantitative RNA analysis of HER2 may help you find out.